The litigation centers on allegations that Dun & Bradstreet’s March 2025 merger announcement and subsequent proxy materials contained materially misleading information. The complaint claims the company portrayed the transaction as an arm's-length strategic review while allegedly omitting Executive Chairman Foley’s personal interest in an expedited sale. Furthermore, investors contend the firm failed to disclose Bank of America Securities’ valuations of superior alternatives and neglected to reveal significant ties between Foley and the company’s financial advisors.
In section Releases
Investors Face November Deadline in Dun & Bradstreet Securities Suit
Investors who held or sold Dun & Bradstreet Holdings, Inc. stock during the 2025 merger with Clearlake Capital Group affiliates have until November 10, 2026, to seek lead plaintiff status in a pending securities fraud class action lawsuit filed by the Rosen Law Firm.
Those eligible to participate include individuals who sold DNB common stock between May 13 and August 26, 2025, exchanged shares in the $9.15-per-share merger, or held shares as of the May 9, 2025, record date. While no class has been certified yet, prospective lead plaintiffs must file their motions with the court by the November deadline. Investors wishing to participate or obtain more information may contact Phillip Kim at the Rosen Law Firm, which is handling the case on a contingency fee basis.
Comments (0)
No comments yet. Be the first!